> Detailanzeige

Al Jurdi, Ayman; Gassen, Rodrigo B.; Borges, Thiago J.; Solhjou, Zhabiz; Hullekes, Frank E.; Lape, Isadora T.; Efe, Orhan; Alghamdi, Areej; Patel, Poojan; Choi, John Y.; Mohammed, Mostafa T.; Bohan, Brigid; Pattanayak, Vikram; Rosales, Ivy; Cravedi, Paolo; Kotton, Camille N.; Azzi, Jamil R.; Riella, Leonardo V.

Non-Invasive Monitoring for Rejection in Kidney Transplant Recipients After SARS-CoV-2 mRNA Vaccination

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Non-Invasive Monitoring for Rejection in Kidney Transplant Recipients After SARS-CoV-2 mRNA Vaccination
  • Beteiligte: Al Jurdi, Ayman; Gassen, Rodrigo B.; Borges, Thiago J.; Solhjou, Zhabiz; Hullekes, Frank E.; Lape, Isadora T.; Efe, Orhan; Alghamdi, Areej; Patel, Poojan; Choi, John Y.; Mohammed, Mostafa T.; Bohan, Brigid; Pattanayak, Vikram; Rosales, Ivy; Cravedi, Paolo; Kotton, Camille N.; Azzi, Jamil R.; Riella, Leonardo V.
  • Erschienen: Frontiers Media SA, 2022
  • Erschienen in: Frontiers in Immunology, 13 (2022)
  • Sprache: Ohne Angabe
  • DOI: 10.3389/fimmu.2022.838985
  • ISSN: 1664-3224
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: IntroductionStudies have shown reduced antiviral responses in kidney transplant recipients (KTRs) following SARS-CoV-2 mRNA vaccination, but data on post-vaccination alloimmune responses and antiviral responses against the Delta (B.1.617.2) variant are limited.Materials and methodsTo address this issue, we conducted a prospective, multi-center study of 58 adult KTRs receiving mRNA-BNT162b2 or mRNA-1273 vaccines. We used multiple complementary non-invasive biomarkers for rejection monitoring including serum creatinine, proteinuria, donor-derived cell-free DNA, peripheral blood gene expression profile (PBGEP), urinary CXCL9 mRNA and de novo donor-specific antibodies (DSA). Secondary outcomes included development of anti-viral immune responses against the wild-type and Delta variant of SARS-CoV-2.ResultsAt a median of 85 days, no KTRs developed de novo DSAs and only one patient developed acute rejection following recent conversion to belatacept, which was associated with increased creatinine and urinary CXCL9 levels. During follow-up, there were no significant changes in proteinuria, donor-derived cell-free DNA levels or PBGEP. 36% of KTRs in our cohort developed anti-wild-type spike antibodies, 75% and 55% of whom had neutralizing responses against wild-type and Delta variants respectively. A cellular response against wild-type S1, measured by interferon-γ-ELISpot assay, developed in 38% of KTRs. Cellular responses did not differ in KTRs with or without antibody responses.ConclusionsSARS-CoV-2 mRNA vaccination in KTRs did not elicit a significant alloimmune response. About half of KTRs who develop anti-wild-type spike antibodies after two mRNA vaccine doses have neutralizing responses against the Delta variant. There was no association between anti-viral humoral and cellular responses.
  • Zugangsstatus: Freier Zugang